---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-237832"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2026-05-26T11:05:16+00:00"
generated_at: "2026-05-26T11:14:23.093292+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Olema partners with Bayer for OP-3136 + darolutamide Phase 1b/2 in mCRPC; 36 patients, H2 2026 start

## Summary
- Olema and Bayer will evaluate OP-3136 (KAT6 inhibitor) combined with darolutamide in ~36 mCRPC patients.
- Phase 1b/2 study expected to initiate in second half of 2026; Bayer supplies darolutamide.
- Olema retains full global commercial and marketing rights to OP-3136; clinical data and inventions jointly owned.
- First clinical collaboration for OP-3136; builds on ongoing Phase 1/2 monotherapy and combination studies.
- Olema to present initial Phase 1 OP-3136 monotherapy data at ASCO on May 30, 2026.

## SEC filing metadata
- accession: 0001193125-26-237832
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2026-05-26T11:05:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/0001193125-26-237832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/olma-20260526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-237832
- JSON: https://secwatch.observer/filing/0001193125-26-237832.json
- Plain text: https://secwatch.observer/filing/0001193125-26-237832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.